Sonic Healthcare Ltd banner

Sonic Healthcare Ltd
F:SAB

Watchlist Manager
Sonic Healthcare Ltd Logo
Sonic Healthcare Ltd
F:SAB
Watchlist
Price: 11.946 EUR 1.01%
Market Cap: €5.7B

Sonic Healthcare Ltd
Investor Relations

Sonic Healthcare is a medical diagnostics company. It runs networks of pathology laboratories, medical centers, and other testing services that help doctors diagnose illness and monitor treatment. It also provides some radiology and related healthcare services in a few markets. Its main customers are doctors, hospitals, clinics, insurers, and public health systems, plus patients who need tests. Sonic makes money by charging for each test or service it performs, with much of that work paid for through health insurance or government reimbursement. In simple terms, it sits in the middle of the healthcare system and turns lab samples and scans into the information doctors need. What makes Sonic’s business model different is that it is built around a large, decentralized network of local laboratories rather than one single product. Demand is tied to everyday medical care, so the business depends less on a one-time sale and more on repeat testing from patients and physicians over time.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2026
Call Date
Feb 18, 2026
AI Summary
Q2 2026

Revenue Growth: Sonic Healthcare reported first-half FY26 revenue of $5.445 billion, with organic growth of 5% and strong top-line momentum across key markets.

Profitability: Net profit was $262 million and earnings per share reached AUD 0.531. EBITDA was $907 million, with margins up 30 basis points versus the prior year.

Guidance Reaffirmed: Full-year EBITDA guidance of $1.87–$1.95 billion (constant currency) was reaffirmed, and depreciation guidance was lowered.

Dividend Increase: Progressive interim dividend of AUD 0.45, up 2.3% on the prior year, with a 60% franking level.

Cost Control & Leverage: Management emphasized ongoing cost control, especially labor, operating leverage, and synergy realization as drivers of margin improvement.

US Operations: Operating review and restructuring is underway in the US, aiming to rationalize anatomical pathology and improve profitability; margin impact expected to lessen in H2.

Capital Management: Several property sale and leaseback initiatives are in progress, with potential proceeds earmarked for share buybacks.

FX Impact: Currency tailwind in H1 will be lower for the full year; H2 faces a currency headwind based on current rates.

Key Financials
Revenue
$5.445 billion
EBITDA
$907 million
Net Profit
$262 million
Earnings Per Share
AUD 0.531
Organic Revenue Growth
5%
Dividend
AUD 0.45
Dividend Franking
60%
Debt Cover Ratio
2.5x
Available Headroom
$1 billion before interim dividend payment
Effective Tax Rate
27%
Earnings Call Recording
Other Earnings Calls
2026

Management

Dr. Colin Stephen Goldschmidt F.A.C.I.D., F.A.I.C.D., F.R.C.P.A., M.B.B.Ch.
CEO, MD & Executive Director
No Bio Available
Mr. Christopher David Wilks B.Com., F.A.C.I.D., F.A.I.C.D.
Finance Director, CFO & Executive Director
No Bio Available
Mr. Peter Savage
Chief Business Officer
No Bio Available
Dr. Stephen Fairy
Global Chief Medical Officer
No Bio Available
Mr. David Byrne
Chief Executive Officer of Sonic Healthcare UK
No Bio Available
Mr. Paul J. Alexander B.Ec., C.A., F.Fin
Deputy CFO & Company Secretary
No Bio Available
Dr. Julian Adler
Chief Executive Officer of Sonic Healthcare Australia - Radiology
No Bio Available

Contacts

Address
NEW SOUTH WALES
Sydney
Level 22, Grosvenor Place, 225 George Street
Contacts